Balchem ((BCPC)) announced an update on their ongoing clinical study.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Balchem Corporation, in collaboration with Pharmavite LLC and Biofortis, Inc., is conducting a clinical trial titled ‘A Randomized, Parallel, Double-Blind, Placebo-Controlled Study to Assess Cognitive Effects of Cognitive Nutritional Supplementation in the General Population.’ The study aims to evaluate the cognitive effects of a nutritional supplement on attention and focus in adults in the United States over a 12-week period. This research is significant as it could provide insights into non-pharmaceutical interventions for cognitive enhancement.
The study is testing a dietary supplement known as the Cognitive Nutritional Supplement, designed to improve cognitive parameters related to attention and focus. Participants will receive either the active supplement or a placebo, allowing researchers to compare outcomes between the two groups.
This interventional study is randomized with a parallel assignment and double-blind masking, meaning neither participants nor investigators know who receives the supplement or placebo. The primary purpose is treatment-focused, aiming to determine the supplement’s efficacy in enhancing cognitive functions.
The trial began on February 14, 2025, with primary completion expected shortly thereafter. The latest update was submitted on April 10, 2025. These dates are crucial as they mark the study’s progress and timeline for potential results.
For investors, this study could influence Balchem’s stock performance, as positive results might boost market confidence and interest in cognitive supplements. Competitors in the cognitive health industry may also be impacted, depending on the study’s outcomes.
The study is currently ongoing, with further details available on the ClinicalTrials portal.